Industrial Chemicals (Fees and Charges) Rules 2020

The Rules introduce and rely on a small set of interlocking concepts. Several are definitional; others are procedural mechanisms that change the financial calculus for different types of applications.

Definitions and cross‑references. Section 4 supplies the definitions used throughout. Key definitional items are:

• "Act", meaning the Industrial Chemicals Act 2019 (s 4);
• "General Rules", meaning the Industrial Chemicals (General) Rules 2019 (s 4);
• "comparable hazard assessment", a written assessment of environmental and/or human health hazard characteristics produced by one of a listed set of domestic or international agencies, including the Executive Director, Therapeutic Goods Administration, APVMA, Environment and Climate Change Canada, multiple European scientific committees, Food Standards Australia New Zealand, Health Canada, and the United States Environmental Protection Agency (s 4);
• "import response" and country categories A, B, C, which depend on a party’s status under the Rotterdam Convention and the content of its import response to that Convention (s 4).

Fee schedule as primary mechanism. The central substantive concept is a fee table (s 5(1)) that assigns an amount to each specified application type. The list defines the state’s charge for a wide range of transactions under the Act and the General Rules: registration, assessment certificates, coverage by certificates, variation of certificates and Inventory entries, commercial evaluation applications and holders, approvals to introduce or export, and confidential business information applications.

Risk‑tiered pricing for assessment certificates. For applications under s 31 (assessment certificates for introduction), the instrument adopts a risk‑based fee methodology (s 5(2)). The fee is a function of the indicative human health risk and indicative environment risk as those terms are defined in the General Rules and Chapter 2 of the General Rules describes how to determine them (s 5(2) note). A 2x2 matrix produces fees at four levels: $7,670; $24,100; $24,100; and $36,050, depending on combinations of very low/low versus medium/high/undetermined risk. There is a single alternative fee of $18,060 where an applicant provides a comparable hazard assessment (s 5(2)(b)). The instrument therefore creates a financial incentive to quantify and document lower hazard profiles or to rely on accepted external assessments.

Related and multi‑component applications. The Rules recognise economies of scope. If a person lodges multiple s 31 applications simultaneously for similar chemicals with the same end use, the first application pays the table amount and each related application is charged $7,235 (s 5(3)). If the related applications are for component chemicals intended as part of the same multi‑component introductions, the related applications pay $2,735 (s 5(4)). The instrument defines the conditions for qualifying as "multi‑component introductions" (s 5(5)): unique identification of component chemicals, manufacture together, introduced and used together without separation, and absence of a single CAS name that covers only the components.

Lower‑of rule. Where multiple fee calculations could apply, s 5(6) prescribes that the lower amount applies.

Discretionary relief. Section 6 allows the Executive Director to refund overpayments of registration charge within three years after the end of the registration year either on initiative or on written application (s 6). Section 7 implements a waiver mechanism tied to application withdrawal: the Executive Director may waive all or part of a fee on withdrawal before decision, must have regard to costs incurred in considering the application when deciding whether to waive, and must refund any waived amount (s 7(2)-(4)).

Interaction with international regulatory outputs. The definitions and fee items incorporate outputs from international regimes and foreign authorities. Category A/B/C country status crucial to export fee item 20 is derived from the Rotterdam Convention import response database (s 4 note; s 5(1) item 20). The comparable hazard assessment concept explicitly names foreign regulatory bodies whose hazard evaluations, if provided to meet the Rules’ definition, alter the fee for s 31 applications (s 4; s 5(2)(b)).

Confidential business information pathway. The instrument charges fees for applications to treat proper names, end uses, or other information as confidential business information under ss 105, 111 and 113 of the Act (s 5(1) items 15-18). Fees vary by the type of confidentiality claim and whether it is an initial claim or a continuation.

Transitional and consequential link. Item 21 references a transitional provision in Schedule 2 of the Industrial Chemicals (Consequential Amendments and Transitional Provisions) Act 2019 and specifies a fee for a person to be taken to be a confidence holder for a confidential Inventory listing (s 5(1) item 21). That ties the fee schedule into the transitional architecture for the Act.

These concepts together create a fee regime that is both prescriptive (specific dollar amounts for enumerated transactions) and conditional (risk banding, comparable hazard assessments, related and multi‑component discounts, country categories). The Rules therefore translate regulatory distinctions into monetary signals that will affect applicants’ choices about how they prepare and present information and how they structure multiple applications.

The Rules primarily affect natural persons and legal entities that interact with the Industrial Chemicals regulatory regime under the Act and the General Rules. That includes, concretely:

• Applicants seeking registration under s 16 and registrants who must pay registration charges; item 1 sets a registration application fee of $80 (s 5(1) item 1). Overpayments of registration charge are refundable under s 6, subject to time limits.

• Parties seeking assessment certificates for introduction under s 31. Item 2 makes the applicable fee a function of the s 31 fee matrix (s 5(2) table) or, where an applicant provides a comparable hazard assessment, a fixed amount of $18,060 (s 5(2)(b)). Applicants who prepare multiple similar applications or multi‑component applications also have different fees available (s 5(3)-(5)).

• Persons who seek to be covered by an assessment certificate, to be removed as covered, to be added as a holder of a certificate, or to be removed as a holder. Items 3 to 6 set fees for these actions: $1,540 to be added as a holder or to list an industrial chemical on the Inventory; $830 for removal as a person covered or as a holder (s 5(1) items 3-6, 12).

• Applicants seeking variations to certificates (s 43) or variations to Inventory listings (ss 87, 88). Fees for variations are set at $4,885 for certificate variations and $4,885 for Inventory listing variations (s 5(1) items 7 and 14).

• Applicants for commercial evaluation authorisations (s 53) and related holder changes (s 60). The initial application fee for a commercial evaluation authorisation is $6,695 (s 5(1) item 8). Adding a holder is $1,540 and removal $830 (s 5(1) items 9-10). Varying a commercial evaluation authorisation is $2,605 (s 5(1) item 11).

• Persons applying to list an industrial chemical on the Inventory (s 83(1)), with an associated fee of $1,540 (s 5(1) item 12).

• Entities asserting confidentiality claims under ss 105, 111, 113 of the Act for proper name, end use, or other information. Fees for initial confidentiality claims (proper name $1,785; end use $625; other information $1,190) and for continuation of confidentiality ($4,710) are specified (s 5(1) items 15-18).

• Exporters seeking approval to export an industrial chemical under General Rules s 74. Item 20 prescribes different fees for export approvals depending on the destination country’s category under the Rotterdam Convention import responses,$2,470 for category A, $4,930 for category B, and $2,470 for category C (s 5(1) item 20; s 4).

• Persons covered by transitional provisions in the consequential amendments and transitional Act; item 21 sets a fee of $4,230 for being taken to be a confidence holder under that Schedule (s 5(1) item 21).

The Rules also affect intermediaries and advisors who prepare applications: consultants, regulatory affairs specialists, and labs producing hazard assessments. The definition of "comparable hazard assessment" (s 4) directly affects those who can produce or supply material that changes the fee for s 31 applications. The allocation of fee reductions for related or multi‑component applications (s 5(3)-(5)) affects how applicants bundle filings and organise product portfolios.

Administratively, the Executive Director is affected as the decision‑maker with power to refund overpayments (s 6) and to waive application fees on withdrawal (s 7). Those discretionary powers impose procedural obligations on the Executive Director (for example, to have regard to costs incurred when considering whether to waive a fee, s 7(3)) and create potential operational workload for the relevant department.

Finally, because the Rules rely on external documents and bodies to determine risk (General Rules Chapter 2 for risk determination) and comparable hazard assessment origins (s 4), regulatory agencies and foreign authorities listed in s 4 are indirectly implicated: their assessments, classifications and import responses have real financial consequences for applicants under these Rules.

In sum, the affected population is industry participants who apply under the Act or General Rules, their advisers, and the Executive Director and departmental resources required to administer refunds, waivers and fee collection.

The Rules convert statutory duties under the Act into concrete payment obligations and give specific administrative rights to applicants and to the Executive Director. The key duties and rights are as follows.

Duty to pay the correct fee when making an application. Section 5(1) prescribes that, for the purposes of paragraph 167(1)(f) of the Act, applicants must accompany an application of the specified kind with the amount listed in the fee table. The table lists dollar amounts against specific application types. This creates a clear duty to calculate and remit the applicable fee at the time of lodging the application.

Obligation to determine applicable fee methodology for s 31 applications. For an application under s 31 (assessment certificate for introduction), the applicant must determine the applicable amount by reference to the risk matrix in s 5(2) or the alternative comparable hazard assessment fee (s 5(2)(b)). That requires using the General Rules to determine the indicative human health risk and the indicative environment risk (s 5(2) note referencing Chapter 2 of the General Rules). The applicant is responsible for selecting and substantiating the correct risk categories for the application of the fee schedule.

Duty to evidence related or multi‑component status if seeking reduced fees. If an applicant seeks the reduced fees for related applications or multi‑component introductions (s 5(3)-(5)), they must make multiple applications at the same time and satisfy the criteria set out for similarity, same end use, or the multi‑component conditions (unique identification, manufactured together, used together without separation, and absence of a single CAS covering all components). Those facts will need to be recorded and available to the Executive Director.

Right to a refund of overpayment of registration charge. Section 6 gives the Executive Director the power to refund an overpayment of registration charge on behalf of the Commonwealth either on the Executive Director’s initiative at any time within three years after the end of the registration year, or if the person applies in writing within that three‑year period. The right is conditioned on time limits: the refund window is three years after the end of the registration year (s 6).

Right to waiver and refund on withdrawal, subject to discretion and consideration of costs incurred. Section 7 allows the Executive Director to waive the whole or part of an application fee where the applicant withdraws before a decision on the application. The Executive Director’s power is discretionary and the decision‑maker must have regard to costs incurred in considering the application (s 7(2)-(3)). If the waiver is granted, the Executive Director must refund the waived amount (s 7(4)). This creates an administrative right to seek fee relief upon voluntary withdrawal, tempered by the agency’s assessment of work already done.

Duty to use specified authoritative sources for comparable hazard assessments. The definition of "comparable hazard assessment" in s 4 lists specific agencies whose written hazard assessments qualify for the special $18,060 fee for s 31 applications (s 5(2)(b)). Applicants relying on a comparable hazard assessment must supply a written assessment from one of the named entities; assessments from other sources are not recognised by the Rules.

Duty to use Rotterdam Convention import responses for export fee categorisation. For export approvals under General Rules s 74 (item 20), the fee is determined by whether the destination country is category A, B or C as defined in s 4. Categories A and B depend on the country being a party to the Rotterdam Convention and the content of its import response. The applicant bears the duty to identify correctly the destination country’s category when calculating the fee.

Right to have the lower applicable fee apply when multiple fee calculations would both apply. Section 5(6) provides a default rule that if paragraphs (2)(a) and (2)(b) both apply to an application, the lower of the applicable amounts applies. That protects applicants against dual calculations producing a higher aggregated fee.

Administrative duties on the Executive Director. The Executive Director has defined duties: to administer refunds under s 6 within the three‑year timeframe and to consider waiver requests under s 7, having regard to costs incurred. The Executive Director is required to refund waived fees when waiver is granted (s 7(4)).

What the Rules do not create. The instrument does not create detailed payment enforcement mechanisms, criminal penalties for non‑payment, or a schedule of interest on late payments within its text. Enforcement and consequences for failure to pay are matters for the Act itself and administrative practice; the Rules focus on amounts, categorisations and limited refund and waiver procedures.

These duties and rights together map the financial interactions between applicants and the regulator: applicants must calculate and pay the correct fee at lodging, can seek refunds of overpayments within a set timeframe, and can request waiver on withdrawal; the Executive Director holds discretion and administrative obligations to implement refunds and waivers and must have regard to incurred costs.

The Rules are a fees instrument and do not themselves create detailed penalties or a new enforcement regime. The text establishes fee amounts and limited administrative remedies but refers to the Act for enforcement mechanisms. The following outlines the enforcement and penalty implications that flow from the Rules as written.

No express offences in the Rules. Nowhere in the Rules is a criminal or civil penalty specified for non‑payment, late payment or misrepresentation in fee calculations. The instrument confines itself to prescribing means of calculation and the amounts that "are to accompany an application" (s 5(1)). For offences, sanctions and enforcement procedures, the relevant provisions are in the Industrial Chemicals Act 2019; the Rules do not replicate or amend those enforcement provisions. Practitioners must therefore consult the Act for any consequences following failure to pay applicable fees.

Obligation to accompany application with the fee. The Rules make clear that particular fees are to accompany specified applications for the purposes of paragraph 167(1)(f) of the Act (s 5(1)). That reference implies the Act ties the validity or processing of applications to payment, but the Rules do not elaborate whether non‑payment invalidates an application, delays processing, attracts administrative refusal, or triggers a debt recovery pathway. Those procedural consequences are matters of the Act and departmental practice.

Administrative remedies and discretion. The Rules give the Executive Director discretion to refund overpayments (s 6) and to waive fees upon withdrawal prior to decision, taking into account costs incurred in considering the application (s 7(2)-(4)). Those powers channel two enforcement‑adjacent outcomes:

• Overpayments can be corrected administratively within a three‑year window (s 6). The Executive Director may act on initiative or in response to a written application by the person.
• Fee waivers can be granted, in whole or in part, when an applicant withdraws before decision, but the Executive Director must have regard to costs incurred (s 7(3)).

Potential for administrative review but not specified here. The Rules do not specify internal review or merits review pathways for decisions under s 6 or s 7. The Act may provide external review or appeal rights in relation to decisions of the Executive Director; the Rules do not create or displace those mechanisms.

Interaction with other financial controls not described. The Rules do not specify interest on late refunds, recovery of outstanding fees, or the mechanics for refund payment (for example, whether a refund is paid to the entity that paid the fee or to another party). Those practical enforcement and payment details are left to departmental procedures or the Act.

Practical enforcement effects for applicants. Because the Rules require fees to accompany applications, applicants face immediate compliance risk: if an application is lodged without the appropriate fee, departmental procedures may return the application, treat it as incomplete, or delay assessment. The ability to seek waiver on withdrawal is limited by the Executive Director’s discretion and explicit consideration of costs incurred; this creates an incentive to withdraw early if seeking a refund but also to account for the regulator’s incurred costs.

Export approvals and Rotterdam Convention import responses. For export‑related fees (item 20), the categorisation of the destination country affects the fee payable. Misclassification of country category could result in underpayment with subsequent recovery obligations, though the Rules themselves do not state recovery methods.

In short, the Rules set the monetary obligations and limited relief processes, but rely on the Act and departmental practice for the mechanics of enforcement, recovery and penalties. Practitioners should consult the Act for enforcement provisions and be prepared for administrative consequences if fees are misreported or unpaid.

The Rules are explicitly made under and subordinate to the Industrial Chemicals Act 2019 (s 3) and invoke and rely on other instruments and external legal frameworks. The principal interactions are as follows.

Dependence on the Industrial Chemicals Act 2019. The Rules operate for the purposes of specific provisions of the Act. Section 5 explicitly refers to paragraph 167(1)(f) of the Act as the statutory hook for prescribing the amounts that must accompany applications (s 5(1)). Many fee items are expressly linked to sections of the Act,for example, application fees for registration (s 16) and assessment certificates (s 31), variations (ss 43, 62, 88), confidential business information processes (ss 105, 111, 113), commercial evaluation authorisations (s 53), and Inventory listings (s 83(1)) (s 5(1) table). Thus the Rules are an implementing instrument that gives effect to the Act’s fee‑charging powers.

Interaction with the Industrial Chemicals (General) Rules 2019. The Rules import core technical concepts from the General Rules. The definitions in s 4 reference "environment hazard characteristic", "human health hazard characteristic", "indicative environment risk", and "indicative human health risk" as having the meanings in the General Rules (s 4). Section 5(2) refers applicants to Chapter 2 of the General Rules for how to determine the indicative human health and environment risk. Item 19 and item 20 in the fee table refer to applications under section 74 of the General Rules for approvals to introduce or to export an industrial chemical. Therefore, the fee instrument is functionally coupled to the risk‑assessment and application processes in the General Rules.

Reference to the Rotterdam Convention. The categorisation of countries (category A, B, C) in s 4 is defined by reference to party status under the Rotterdam Convention and the content of a party’s import response to the Secretariat. A note in s 4 points to the Rotterdam Convention website for a database of import responses. That creates a link between international treaty outputs and domestic fee outcomes: an export approval fee is different depending on the destination’s import response (s 5(1) item 20), and the Rules rely on the international database to determine category status (s 4 note).

Connection to the Industrial Chemicals (Consequential Amendments and Transitional Provisions) Act 2019. Item 21 of the fee table in s 5(1) expressly links to subitem 36(2) of Schedule 2 to the consequential and transitional Act, setting a fee for being taken to be a confidence holder for a confidential Inventory listing. This embeds a transitional administrative cost into the broader scheme of implementing legislation.

Interaction with foreign regulatory assessments. The definition of "comparable hazard assessment" in s 4 explicitly lists foreign regulatory bodies and EU scientific committees whose written hazard assessments count for the fee reduction under s 5(2)(b). That list includes agencies such as Environment and Climate Change Canada, Health Canada, the United States Environmental Protection Agency, and various European scientific committees. This creates a cross‑jurisdictional interaction whereby accepted foreign assessments alter the domestic fee payable. It also implicitly imports different substantive hazard assessment standards into the domestic procedural calculus.

Confidentiality provisions in the Act. The Rules set fees for applications under ss 105, 111 and 113 of the Act to treat proper names, end uses or other information as confidential business information (s 5(1) items 15-18). This makes the exercise of confidential business information rights under the Act contingent on payment of defined fees in the Rules.

Administrative law and review. While the Rules do not themselves create appeal or review procedures, they place administrative discretions in the Executive Director (refunds, waivers). Decisions by the Executive Director under these Rules will sit within the administrative law framework established by the Act and general administrative law principles. The Rules’ silence about review means review rights depend on the Act and external judicial or merits review avenues, not on the Rules.

Financial and tax law interfaces. The Rules set monetary obligations for applicants that will have downstream accounting and tax implications for businesses. They also affect departmental appropriations and the Commonwealth’s receipt of fees, but the Rules contain no provisions addressing GST, invoicing mechanics, or the treatment of fee receipts within Commonwealth financial administration legislation.

In summary, the Rules are tightly integrated with the Industrial Chemicals Act 2019 and the General Rules for risk determination, operationally linked to international instruments (Rotterdam Convention) and specific foreign regulatory bodies through the comparable hazard assessment definition, and intersect with transitional provisions in related legislation. Practitioners must consider the Act and General Rules as part of any legal or compliance assessment of the fees.

The instrument identifies itself as the Industrial Chemicals (Fees and Charges) Rules 2020 (s 1). It states that it is made under the Industrial Chemicals Act 2019 (s 3). The text provided contains no express amendment notes, repeal schedules, commencement dates, or recorded changes to the Rules themselves.

What the instrument tells us directly:

• The instrument is dated to 2020 by its title (s 1). No further dating, commencement clause or legislative history is contained in the text that has been supplied.
• The Rules rely on definitions and provisions from the Industrial Chemicals Act 2019 and the Industrial Chemicals (General) Rules 2019; item 21 also references Schedule 2 to the Industrial Chemicals (Consequential Amendments and Transitional Provisions) Act 2019 (s 5(1) item 21). These cross‑references indicate contemporaneous legislative activity in 2019 and 2020 around the implementation of the Act, but do not in themselves show amendments to the fee instrument.

Absence of amendment entries in this text. The provided instrument does not include a schedule of amendments, a notes section showing updates, or any marginal annotations indicating later variations. It contains the original schedule of fees and the refund/waiver provisions as enacted, but nothing in the supplied text signals later increases, indexation, repeal, or replacement.

What this implies for users. Because the Rules set specific dollar amounts, users should treat the amounts in this text as the amounts prescribed by the instrument at the time of its enactment; however, the absence of amendment history in the supplied text means one cannot assume these amounts remain current. Fee instruments are commonly amended by later instruments to update amounts, reflect indexation, or change categories. The Rules themselves do not provide any indexation mechanism or formula for changing amounts over time.

Recommended practical step (procedural, not prescriptive). To ensure current accuracy, practitioners should check the consolidated version of the Rules on the official legislation register or the department’s latest published fee schedules. The text supplied here must be read as a snapshot of the instrument as enacted in 2020; it does not contain later amendment history or confirm current operative figures beyond that snapshot.

In short, the Rules set out a 2020 fee schedule and limited refund and waiver provisions but the supplied text contains no explicit amendment history or notes of subsequent changes. Any analysis that relies on present‑day fee levels should therefore verify whether later amending instruments have altered amounts or procedural provisions.

The instrument contains no references to judicial decisions, litigation, or dispute resolution outcomes. Nowhere in the text does it cite court decisions or state that particular provisions have been the subject of litigation. The Rules are a subordinate legislative instrument prescribing fees and limited administrative procedures; the text provided does not record precedent, contested interpretations, or legal challenges.

What the absence of litigation history in the instrument means practically. Because the Rules set prescribed fees and give discretionary powers to the Executive Director to refund or waive fees, disputes could arise in practice,for example on whether a person properly qualified for a reduced related application fee, on whether a comparable hazard assessment is acceptable, or on whether the Executive Director properly had regard to costs when deciding to waive fees. However, any such cases would appear in the judicial record rather than in the instrument itself. The Rules do not purport to summarise or bind judicial interpretation.

Where to look for litigation outcomes. If an advisor requires information on how courts or tribunals have interpreted the Act or these Rules, the instrument itself does not provide that information. The appropriate sources would be Tribunal decisions, Federal Court judgments or judicial review proceedings concerning decisions made under the Industrial Chemicals Act 2019 by the Executive Director or delegate. The Rules do not provide an index or list of such cases.

Particular issues that could give rise to litigation, based on the Rules’ content. The Rules create several potentially disputable factual and legal issues that could lead to challenge, for example:

• Whether an applicant’s provided hazard assessment qualifies as a "comparable hazard assessment" under s 4; the definition is a closed list of named authorities and may give rise to factual disputes about provenance, scope and equivalence.
• Whether chemicals are "similar" and have the "same end use" for purposes of s 5(3), or whether component chemicals meet the s 5(5) conditions for multi‑component introductions that carry the lower fees.
• Whether the Executive Director properly exercised discretion under s 7 to waive fees and properly had regard to "costs that have been incurred" in considering an application.
• Whether the application of the Rotterdam Convention import responses to categorise countries for export fee calculations (s 4 and s 5(1) item 20) was correctly applied.

However, the Rules themselves do not report judicial treatment of those points. Practitioners needing litigation precedents must consult case law databases and the Act’s decision records; the Rules provide the statutory framework but not the adjudicative history.

In summary, the Rules contain no litigation history by themselves. Any litigation or tribunal outcomes about the application, interpretation or validity of these Rules would need to be sourced from external judicial or tribunal records.

The Rules are concise but contain several practical traps and friction points that will affect applicants, advisers and regulators. The following are concrete issues identified from the text, with the relevant provisions cited.

Risk‑tiered fee escalation (s 5(2)). The fee for a s 31 application can range significantly: $7,670 up to $36,050 depending on the cross‑classification of indicative human health risk and indicative environment risk determined under the General Rules (s 5(2) table). If either risk is undetermined at lodgement, higher fees apply ($24,100 or $36,050). Applicants who do not complete risk assessment work before lodging will likely face the higher bracket. The "undetermined" category therefore has a direct cost consequence.

Comparable hazard assessment limited list (s 4; s 5(2)(b)). The reduced s 31 fee of $18,060 applies only where the application includes a "comparable hazard assessment" as defined in s 4, and that definition is a closed list of named authorities. Assessments from other credible organisations will not qualify under this instrument. Clients should confirm that any external hazard assessment they intend to rely on comes from one of the listed entities.

Related application fee mechanics (s 5(3)-(5)). The reduced related‑application fees ($7,235 for similar chemicals with same end use; $2,735 for components of multi‑component introductions) require simultaneous lodgement with the first application. Late or staggered lodgements will lose the reduced rate. For multi‑component introductions, the Rules require each component to be uniquely identifiable, manufactured together, used together without separation, and not covered by a single CAS that describes all components (s 5(5)). Failure to document or prove those four conditions will jeopardise eligibility for the lower fee.

Lower‑of rule applies only to certain paragraphs (s 5(6)). Section 5(6) provides that if paragraphs (2)(a) and (2)(b) both apply, the lower amount applies. That lower‑of protection is not expressed as a general fallback for all possible overlapping fee computations. Practitioners must be careful when multiple fee rules could arguably apply to an application; only the specific cross‑reference in s 5(6) gives an explicit lower‑of rule.

Export fee oddity linked to Rotterdam import responses (s 4; s 5(1) item 20). The export fee is higher for category B countries ($4,930) compared with categories A and C ($2,470). Category B includes parties to the Rotterdam Convention that either gave "no consent" or did not provide an import response. That means exporting to countries that have not provided a consent in the Convention framework can cost more, and the domestic fee depends on international data that can change. Practitioners must verify the destination’s current import response status when calculating fees.

Confidentiality fees vary and continuation fee is large (s 5(1) items 15-18). Initial fees for confidentiality claims vary substantially: $1,785 for proper name, $625 for end use, $1,190 for other information. The fee to continue confidentiality under s 111 is $4,710 (s 5(1) item 17). Continuing confidentiality is substantially more expensive than an initial end‑use claim, which warrants planning and budgeting for long‑term confidentiality maintenance.

Refund time limit for registration overpayments (s 6). Refunds of overpaid registration charges must be claimed within three years after the end of the registration year unless the Executive Director acts on their own initiative (s 6). That creates a finite statutory window for corrective claims and record retention requirements.

Waiver on withdrawal is discretionary and cost‑sensitive (s 7). If an applicant withdraws before decision, the Executive Director may waive the whole or part of the fee but must have regard to costs that have been incurred in considering the application (s 7(2)-(3)). Applicants cannot assume automatic refunds on withdrawal; late withdrawals after substantial departmental work are likely to attract smaller waivers if any.

No indexation or amendment mechanism in the text. The Rules set dollar amounts but do not provide an automatic indexation mechanism or formula for adjusting fees over time. Fees may be outdated if not amended by later instruments; users must verify current amounts.

Dependence on the General Rules for risk classification. Determination of fees for s 31 applications requires using Chapter 2 of the General Rules for risk characterisations (s 5(2) note). Errors in classifying indicative risks or relying on incomplete hazard data can move an application into a higher fee bracket.

Transitional confidence holder fee (s 5(1) item 21). Item 21 applies to an application under subitem 36(2) of Schedule 2 to the Industrial Chemicals (Consequential Amendments and Transitional Provisions) Act 2019. Transitional arrangements often carry particular eligibility rules; applicants should trace the Schedule 2 clause to understand whether they qualify for this fee category.

Document provenance for comparable hazard assessments. Because the Rules name specific agencies, applicants must ensure that the hazard assessment documents supplied are written assessments attributable to those agencies. Internal reports referencing or summarising an agency’s assessment may not suffice.

In sum, the gotchas are mostly about timing, source provenance, risk classification, bundling of applications, and the discretionary nature of waivers. Each of those concrete mechanics in the Rules has a directly calculable financial impact and an evidentiary burden that applicants must meet to secure lower fees or refunds.

Compliance with these Rules requires accurate identification of the application type, correct fee calculation, timely payment, documentary support for any fee‑reducing claims, and recordkeeping to preserve rights to refunds or waivers. Practical steps follow directly from the text.

1. Identify the correct fee item and confirm statutory linkage. Match your application to the exact Act or General Rules section cited in the fee table (s 5(1)). For example, a s 31 assessment certificate, a s 53 commercial evaluation authorisation, or an application under General Rules s 74 for export approval correspond to specific items in the fee table. Mistaking the item will lead to underpayment or administrative rejection.

2. For s 31 applications, determine the indicative human health and environment risk using Chapter 2 of the General Rules before lodging (s 5(2) note). The fee is derived from the 2x2 matrix in s 5(2). If either risk is undetermined, the fee may default to a higher bracket. Allocate budget and determine whether further data or assessments are needed to establish a lower risk category before lodgement.

3. Consider whether a comparable hazard assessment is available and admissible. If you have a written hazard assessment from one of the authorities named in s 4 (for example, the TGA, APVMA, Health Canada, the US EPA, specified EU committees), including it with a s 31 application changes the applicable fee to $18,060 (s 5(2)(b)). Ensure the assessment is a written assessment meeting the Rules’ definition and is the actual product of the named authority. Keep provenance documents.

4. If lodging multiple s 31 applications, assess whether they are "related applications" or part of the same "multi‑component introductions" and lodge them at the same time if you require the reduced fees (s 5(3)-(5)). For related‑application discounts you need simultaneous lodgement. For multi‑component introductions, document the four conditions in s 5(5): unique identification of component chemicals, manufactured together, used together and not separable during introduction or use, and absence of a single CAS covering all component chemicals.

5. For export approvals, verify the destination country’s Rotterdam Convention status and import response. The export approval fee depends on whether the destination is a category A, B or C country as defined in s 4 and applied in s 5(1) item 20. Verify the relevant import response status at lodgement because fees differ (category B attracts a higher fee).

6. Prepare confidentiality applications carefully and budget for continuation fees. Initial fees differ by claim type (proper name, end use, other information) and continuation of confidentiality under s 111 is significantly more expensive (s 5(1) items 15-18). Keep thorough justification for confidentiality claims and plan for the continuation fee if confidentiality is to be maintained long term.

7. Always pay the fee with the application. The instrument states that the specified amount "is to accompany an application" (s 5(1)). Ensure the application submission process includes proper payment channels and that invoices or remittance advices are retained.

8. Retain financial and documentary records for refunds or waivers. If you overpay a registration charge, you may apply for a refund within three years after the end of the registration year (s 6). File proof of payment and supporting documentation promptly. If you withdraw an application and seek a waiver under s 7, document the timing of withdrawal and any costs you believe were not incurred by the regulator; recognise that the Executive Director must have regard to costs already incurred.

9. Provide clear evidence when asserting fee‑reducing facts. For related applications or multi‑component introductions, preserve contemporaneous documentation establishing similarity, common end use, joint manufacture, or inseparability during use. For comparable hazard assessments, supply the written assessment itself and, if necessary, an explanation of its scope and provenance.

10. Monitor departmental processes for refunds or waivers. The Executive Director has discretion to refund overpayments on initiative within three years (s 6) and to waive fees on withdrawal subject to costs incurred (s 7). Track the progress of any refund application and be prepared to respond to departmental requests for evidence.

11. Consult the Act and General Rules for procedural and enforcement details. Because the Rules do not set out enforcement penalties, processing timelines or appeal rights, consult the Industrial Chemicals Act 2019 and the General Rules for complementary procedural obligations and for the consequences of non‑payment or disputed decisions.

12. Verify current fee amounts before lodgement. The text supplied is the instrument as enacted in 2020. Because the Rules as provided include no indexation or amendment schedule, confirm the currently operative amounts on the formal legislation register or from the administering department before finalising applications and budgets.

Following these steps will align operational practice with the Rules’ requirements: paying the correct fee at lodgement, substantiating any reduced‑fee claim with the evidence the Rules require, preserving the two main administrative relief avenues (refund of overpayment within three years, waiver on withdrawal), and keeping records to support any subsequent administrative action.